Applied Genetic Technologies Corporation logo
Applied Genetic Technologies Corporation AGTC

Quarterly report 2022-Q3
added 11-21-2022

report update icon

Applied Genetic Technologies Corporation Balance Sheet 2011-2026 | AGTC

Annual Balance Sheet Applied Genetic Technologies Corporation

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-36 M -86.2 M -27.7 M -26.7 M -31.1 M -30.7 M -28.9 M -39.2 M -8.62 M -19.6 M 249 K -

Long Term Debt

9.12 M 17.7 M 9.68 M - - - - - - - 16 K -

Long Term Debt Current

1.27 M 1.12 M 1.06 M - - - - - - - - -

Total Non Current Liabilities

- - - 4.15 M 4.96 M 4.44 M 16.8 M - - - 32.6 M -

Total Current Liabilities

25.2 M 19.7 M 13 M 9.36 M 14.4 M 28.2 M 54.7 M 4.64 M 2.53 M - - -

Total Liabilities

37.2 M 41.2 M 29.3 M 13.5 M 19.4 M 32.6 M 71.5 M 4.64 M 2.53 M 1.36 M 34.1 M -

Deferred Revenue

- - - - 6.3 M 21 M 46.9 M - - 212 K - -

Retained Earnings

-308 M -239 M -181 M -136 M -111 M -89.6 M -90 M -88.7 M -64.3 M -48.4 M -43.4 M -

Total Assets

66.7 M 127 M 100 M 92.2 M 119 M 148 M 181 M 90.2 M 77.4 M 36.2 M 2.82 M -

Cash and Cash Equivalents

46.4 M 105 M 38.5 M 26.7 M 31.1 M 30.7 M 28.9 M 39.2 M 8.62 M 8.89 M 774 K -

Book Value

29.5 M 85.8 M 71 M 78.7 M 99.2 M 115 M 109 M 85.5 M 74.9 M 34.8 M -31.3 M -

Total Shareholders Equity

29.5 M 85.8 M 71 M 78.7 M 99.2 M 115 M 109 M 85.5 M 74.9 M -36.2 M -31.3 M -

All numbers in USD currency

Quarterly Balance Sheet Applied Genetic Technologies Corporation

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- 6.81 M 9.12 M 11.4 M 13.5 M 15.7 M 17.7 M 17.7 M 9.84 M 9.76 M 9.68 M 9.68 M 63 K 75 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- 39.7 M 37.2 M 40.2 M 40.9 M 40.9 M 41.2 M 41.2 M 30.4 M 29.4 M 29.3 M 29.3 M 22.2 M 16.7 M 13.5 M 13.5 M 32.1 M 38.4 M 19.4 M 19.4 M 19.8 M 23.6 M 32.6 M 32.6 M 48 M 58.9 M 71.5 M 71.5 M 94.1 M 113 M 4.64 M 4.64 M 2.72 M 3.24 M 2.53 M 2.53 M - 3.57 M 3.57 M - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - 12.7 M 16.3 M 6.3 M 8.19 M 11.9 M 14.7 M 21 M 21 M - - 46.9 M - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- -327 M -308 M -290 M -276 M -256 M -239 M -239 M -212 M -197 M -181 M -181 M -156 M -147 M -136 M -136 M -137 M -132 M -111 M -111 M -96.2 M -91 M -89.6 M -89.6 M -84.3 M -86.4 M -90 M -90 M -94.7 M -97.8 M -88.7 M -88.7 M -74.4 M -69.7 M -64.3 M -64.3 M - -48.4 M -48.4 M - - - - - - - - -

Total Assets

- 57.3 M 66.7 M 87.2 M 92.4 M 110 M 127 M 127 M 72 M 85.6 M 100 M 100 M 82.3 M 84.6 M 92.2 M 92.2 M 108 M 117 M 119 M 119 M 131 M 139 M 148 M 148 M 166 M 173 M 181 M 181 M 196 M 210 M 90.2 M 90.2 M 101 M 105 M 77.4 M 77.4 M - 25.5 M 25.5 M - - - - - - - - -

Cash and Cash Equivalents

- 34.2 M 46.4 M 67.8 M 72.8 M 90.5 M 105 M 105 M 19.1 M 31.6 M 38.5 M 38.5 M 18.1 M 16.3 M 26.7 M 26.7 M 24 M 26.5 M 31.1 M 31.1 M 70.3 M 48.7 M 30.7 M 30.7 M 42.5 M 56 M 42.5 M 56 M 44.4 M 140 M 44.4 M 140 M 44.2 M 46.8 M 44.2 M 46.8 M 9 M 7.86 M 8.89 M 5.56 M - - 774 K - - - 1.83 M -

Book Value

- 17.6 M 29.5 M 47 M 51.5 M 69.5 M 85.8 M 85.8 M 41.5 M 56.2 M 71 M 71 M 60 M 68 M 78.7 M 78.7 M 76 M 78.9 M 99.2 M 99.2 M 112 M 115 M 115 M 115 M 118 M 114 M 109 M 109 M 102 M 97.4 M 85.5 M 85.5 M 98.1 M 102 M 74.9 M 74.9 M - 21.9 M 21.9 M - - - - - - - - -

Total Shareholders Equity

- 17.6 M 29.5 M 47 M 51.5 M 69.5 M 51.5 M 69.5 M 41.5 M 41.5 M 41.5 M 56.2 M 60 M 60 M 60 M 68 M 76 M 76 M 76 M 78.9 M 112 M 115 M 112 M 115 M 118 M 114 M 109 M 109 M 102 M 97.4 M 85.5 M 85.5 M 98.1 M 102 M 74.9 M 74.9 M - -36.2 M -36.2 M - - - -31.3 M - - - -29.4 M -

All numbers in USD currency

Balance Sheet is a fundamental financial report of Applied Genetic Technologies Corporation, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Nanobiotix S.A. Nanobiotix S.A.
NBTX
$ 30.34 -0.82 % $ 286 B franceFrance
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Akebia Therapeutics Akebia Therapeutics
AKBA
$ 1.4 -0.71 % $ 360 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 95.5 3.83 % $ 27.2 B germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.92 -0.34 % $ 6.35 B israelIsrael
Aytu BioScience Aytu BioScience
AYTU
$ 2.55 -0.78 % $ 16 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Amphastar Pharmaceuticals Amphastar Pharmaceuticals
AMPH
$ 20.37 -2.4 % $ 952 M usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.08 -2.16 % $ 436 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 24.21 -1.47 % $ 3.08 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 32.24 -4.1 % $ 2.14 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
- - $ 3.45 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 3.13 -1.26 % $ 315 M usaUSA
Codiak BioSciences Codiak BioSciences
CDAK
- -55.98 % $ 2.15 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
InflaRx N.V. InflaRx N.V.
IFRX
$ 1.0 -2.91 % $ 152 M germanyGermany
Immutep Limited Immutep Limited
IMMP
$ 0.31 -2.52 % $ 1.08 B australiaAustralia
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Akari Therapeutics, Plc Akari Therapeutics, Plc
AKTX
$ 3.83 -2.3 % $ 258 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA